Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
Christopher Poppe, Dimitris Repantis
Current Topics in Behavioral Neurosciences November 8, 2024 DOI: 10.1007/7854_2024_533 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Bioethics Clinical ethics Psychedelic-assisted treatments Research ethics |
| Citations | 9 |
| Key points | Argues that ethical integrity in psychedelic-assisted treatments requires attention to autonomy, vulnerability, therapist training, and equitable access, alongside pressing concerns for indigenous justice and the impact of legalization. |
Abstract
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and at the intersection of psychedelic medicine and society. In contrast to earlier psychedelic research, nowadays medical ethics have been firmly established as a discipline regulating patient-physician relationships which highlight the importance of autonomy, shared decision-making and informed consent in clinical ethics. During and after altered states of consciousness, autonomy is particularly important as participants are in a vulnerable state. In this vulnerable state, both touch and suggestibility are central ethical concerns. In turn, the debate surrounding hallucinogenic and nonhallucinogenic psychedelic substances discusses the importance of altered states of consciousness in general. Of further concern are exceptional training requirements and competencies of psychedelic therapists, as well as the particular context of end-of-life care. Lastly, this section discusses how ethical integrity in clinical treatments can be supported through institutions. In research ethics, inclusivity, research equipoise, and expectation management are key issues in the participation and trials, while open question for the posttrial access to care after psychedelic trials remain. Finally, the chapter addresses the question of equitable access to psychedelic medicine. Furthermore, justice for indigenous communities using psychedelics and the impact of legalization and medicalization of psychedelic substances are pressing ethical concerns amidst the "psychedelic renaissance."
Citations in the library
Cited by 10
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
- Classifying Psychedelic-Related Complications Current Topics in Behavioral Neurosciences 2026
- Enhanced independence: De-biasing processes in psychedelic research and beyond Research Ethics April 2, 2025
- Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder. Annals of Medicine and Surgery 2026
- Klassische Halluzinogene in der Behandlung von Suchterkrankungen – Ein narrativer Überblick Suchttherapie August 1, 2026
and 5 more in the library
Cites 54
- A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021
- The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects ACS Pharmacology & Translational Science December 10, 2020
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
- Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape JAMA Psychiatry March 29, 2023
- Ethics and ego dissolution: the case of psilocybin Journal of Medical Ethics May 27, 2020
and 49 more in the library